CN1109554C - 一种治疗过敏性紫癜病的药 - Google Patents
一种治疗过敏性紫癜病的药 Download PDFInfo
- Publication number
- CN1109554C CN1109554C CN00123995A CN00123995A CN1109554C CN 1109554 C CN1109554 C CN 1109554C CN 00123995 A CN00123995 A CN 00123995A CN 00123995 A CN00123995 A CN 00123995A CN 1109554 C CN1109554 C CN 1109554C
- Authority
- CN
- China
- Prior art keywords
- radix
- blood
- portions
- medicine
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 title claims abstract description 35
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 title claims abstract description 35
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 title claims abstract description 13
- 229940079593 drugs Drugs 0.000 title claims description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 41
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 41
- 241000222336 Ganoderma Species 0.000 claims abstract description 37
- 241000555682 Forsythia x intermedia Species 0.000 claims abstract 2
- 241000628997 Flos Species 0.000 claims description 76
- 241000209020 Cornus Species 0.000 claims description 72
- 241000756943 Codonopsis Species 0.000 claims description 37
- 239000009636 Huang Qi Substances 0.000 claims description 36
- 241001550206 Colla Species 0.000 claims description 35
- 241000245240 Lonicera Species 0.000 claims 1
- 241000545442 Radix Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 201000010099 disease Diseases 0.000 abstract description 35
- 230000001225 therapeutic Effects 0.000 abstract description 5
- 229940107666 ASTRAGALUS ROOT Drugs 0.000 abstract 1
- 240000001992 Angelica archangelica Species 0.000 abstract 1
- 210000003056 Antler Anatomy 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 240000008537 Burchellia bubalina Species 0.000 abstract 1
- 235000004415 Burchellia bubalina Nutrition 0.000 abstract 1
- 240000000774 Cunila origanoides Species 0.000 abstract 1
- 235000018274 Cunila origanoides Nutrition 0.000 abstract 1
- 235000014866 Dictamnus albus Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 240000004600 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241001149655 Rubia tinctorum Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002349 favourable Effects 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 231100000224 toxic side effect Toxicity 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 121
- 210000004369 Blood Anatomy 0.000 description 118
- 210000004185 Liver Anatomy 0.000 description 45
- 208000002193 Pain Diseases 0.000 description 35
- 230000036407 pain Effects 0.000 description 35
- 210000000952 Spleen Anatomy 0.000 description 31
- 238000010410 dusting Methods 0.000 description 30
- 238000005303 weighing Methods 0.000 description 30
- 210000000214 Mouth Anatomy 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 210000003734 Kidney Anatomy 0.000 description 25
- 239000007788 liquid Substances 0.000 description 24
- 239000007789 gas Substances 0.000 description 22
- 239000000843 powder Substances 0.000 description 21
- 230000001737 promoting Effects 0.000 description 20
- 235000009508 confectionery Nutrition 0.000 description 18
- 210000002784 Stomach Anatomy 0.000 description 17
- 238000001816 cooling Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 206010018987 Haemorrhage Diseases 0.000 description 16
- 210000004072 Lung Anatomy 0.000 description 15
- 206010037549 Purpura Diseases 0.000 description 15
- 241001672981 Purpura Species 0.000 description 15
- 230000023597 hemostasis Effects 0.000 description 15
- 210000002216 Heart Anatomy 0.000 description 14
- 231100000614 Poison Toxicity 0.000 description 14
- 230000002496 gastric Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 208000004880 Polyuria Diseases 0.000 description 13
- 230000035619 diuresis Effects 0.000 description 13
- 230000025627 positive regulation of urine volume Effects 0.000 description 13
- 210000003205 Muscles Anatomy 0.000 description 12
- 210000003491 Skin Anatomy 0.000 description 11
- 230000000268 renotropic Effects 0.000 description 11
- 239000000341 volatile oil Substances 0.000 description 11
- 206010007247 Carbuncle Diseases 0.000 description 10
- 229940023488 Pill Drugs 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 235000012907 honey Nutrition 0.000 description 10
- 230000001717 pathogenic Effects 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000006187 pill Substances 0.000 description 10
- 208000001848 Dysentery Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 206010037844 Rash Diseases 0.000 description 8
- 230000000740 bleeding Effects 0.000 description 8
- 231100000319 bleeding Toxicity 0.000 description 8
- 230000001105 regulatory Effects 0.000 description 8
- 238000005728 strengthening Methods 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 206010040943 Skin ulcer Diseases 0.000 description 7
- 229930013930 alkaloids Natural products 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 201000005884 exanthem Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000010926 purge Methods 0.000 description 7
- 231100000019 skin ulcer Toxicity 0.000 description 7
- 241000668709 Dipterocarpus costatus Species 0.000 description 6
- 206010018836 Haematochezia Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000003932 Urinary Bladder Anatomy 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 230000003177 cardiotonic Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 230000002522 swelling Effects 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 206010016286 Febrile disease Diseases 0.000 description 5
- 206010072736 Rheumatic disease Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 229940076185 Staphylococcus aureus Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000003419 expectorant Effects 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- -1 irony Chemical compound 0.000 description 5
- 101710031899 moon Proteins 0.000 description 5
- 230000001047 pyretic Effects 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 210000001015 Abdomen Anatomy 0.000 description 4
- 206010003246 Arthritis Diseases 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 4
- 229940107161 Cholesterol Drugs 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 210000000232 Gallbladder Anatomy 0.000 description 4
- 229940096919 Glycogen Drugs 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 4
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 description 4
- 206010018830 Haematemesis Diseases 0.000 description 4
- 210000003141 Lower Extremity Anatomy 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- 229960004793 Sucrose Drugs 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000003266 anti-allergic Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 230000001077 hypotensive Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 201000008125 pain agnosia Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000002588 toxic Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N β-Sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 210000001367 Arteries Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 210000001124 Body Fluids Anatomy 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- LQGUBLBATBMXHT-UHFFFAOYSA-N Chrysophanic acid Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 3
- 206010009802 Coagulopathy Diseases 0.000 description 3
- 208000001780 Epistaxis Diseases 0.000 description 3
- 210000003414 Extremities Anatomy 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 229940088597 Hormone Drugs 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 208000008425 Protein Deficiency Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- VXMKYRQZQXVKGB-CWWHNZPOSA-N Tannin Chemical compound O([C@H]1[C@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]([C@H]2O)O1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 VXMKYRQZQXVKGB-CWWHNZPOSA-N 0.000 description 3
- 210000004291 Uterus Anatomy 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 230000000916 dilatatory Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004914 menses Anatomy 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1S,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18β-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 2
- 206010003549 Asthenia Diseases 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- 206010007191 Capillary fragility Diseases 0.000 description 2
- 241000208365 Celastraceae Species 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 229940097043 Glucuronic Acid Drugs 0.000 description 2
- 208000006750 Hematuria Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 241001479541 Lithospermum erythrorhizon Species 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000000865 Mononuclear Phagocyte System Anatomy 0.000 description 2
- 210000004165 Myocardium Anatomy 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 108009000551 Nephrotic syndrome Proteins 0.000 description 2
- 206010029410 Night sweats Diseases 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N Octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 210000004915 Pus Anatomy 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 208000005687 Scabies Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- NEZONWMXZKDMKF-SNVBAGLBSA-N Shikonin Natural products C1=CC(O)=C2C(=O)C([C@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-SNVBAGLBSA-N 0.000 description 2
- 235000000336 Solanum dulcamara Nutrition 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- WCGUUGGRBIKTOS-RRHGHHQTSA-N Ursolic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C)[C@@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2 WCGUUGGRBIKTOS-RRHGHHQTSA-N 0.000 description 2
- 206010049975 Uterine contractions during pregnancy Diseases 0.000 description 2
- 229940088594 Vitamin Drugs 0.000 description 2
- 229940045997 Vitamin A Drugs 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000001396 anti-anti-diuretic Effects 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000001882 diuretic Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000002175 menstrual Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000001568 sexual Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- DTGKSKDOIYIVQL-QXFUBDJGSA-N (-)-borneol Chemical compound C1C[C@]2(C)[C@H](O)C[C@H]1C2(C)C DTGKSKDOIYIVQL-QXFUBDJGSA-N 0.000 description 1
- 229930006703 (-)-borneol Natural products 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-Naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- GCGGSVAWTYHZBI-CVQRFVFPSA-N 1-hydroxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=C3C(=O)C4=CC=CC=C4C(=O)C3=CC=2)O)O1 GCGGSVAWTYHZBI-CVQRFVFPSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- HMUJXQRRKBLVOO-AWEZNQCLSA-N 4'-methoxy-5,7-dihydroxyflavanone Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 HMUJXQRRKBLVOO-AWEZNQCLSA-N 0.000 description 1
- MKMCJLMBVKHUMS-UHFFFAOYSA-N 6-Methoxy-2(3H)-benzoxazolone Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 230000001961 ATP content Effects 0.000 description 1
- 210000003489 Abdominal Muscles Anatomy 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 210000003423 Ankle Anatomy 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010061590 Blood disease Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N Catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- LHDWRKICQLTVDL-IFBNHNBKSA-N Catalpol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@H]2[C@@H](O)[C@H]3[C@](CO)(O3)[C@@H]12 LHDWRKICQLTVDL-IFBNHNBKSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229940074393 Chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N Chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229940015047 Chorionic Gonadotropin Drugs 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 208000000325 Deficiency Disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- HFJRKMMYBMWEAD-UHFFFAOYSA-N Dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N Emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940073144 Glycyrrhetinic acid Drugs 0.000 description 1
- 206010018913 Haemolysis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 Inulin Drugs 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000731961 Juncaceae Species 0.000 description 1
- 201000009672 Keshan disease Diseases 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KBMSVODXFLAQNJ-DXGHHDSJSA-N Linderane Chemical compound C1=2C(C)=COC=2C\C(C)=C\CC[C@@]23C(=O)O[C@@H]1[C@@H]2O3 KBMSVODXFLAQNJ-DXGHHDSJSA-N 0.000 description 1
- KBMSVODXFLAQNJ-ZEBDJQDSSA-N Linderane Natural products O=C1O[C@@H]2[C@@H]3O[C@]13CC/C=C(/C)\Cc1occ(C)c21 KBMSVODXFLAQNJ-ZEBDJQDSSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 208000007106 Menorrhagia Diseases 0.000 description 1
- 206010027327 Menstrual disease Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- UAHWPYUMFXYFJY-UHFFFAOYSA-N Myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- DFPMSGMNTNDNHN-OHXUDFEXSA-N Naringin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 DFPMSGMNTNDNHN-OHXUDFEXSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004678 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 229940081967 Rutin Drugs 0.000 description 1
- 102100012531 SLC25A13 Human genes 0.000 description 1
- 210000002374 Sebum Anatomy 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- 206010027699 Skin injury Diseases 0.000 description 1
- 206010040882 Skin lesion Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 240000002686 Solanum melongena Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N Tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 Tetrodotoxin Drugs 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000001113 Umbilicus Anatomy 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 229940082632 VITAMIN B12 AND FOLIC ACID Drugs 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940046010 Vitamin K Drugs 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229940019697 Vitamin K containing hemostatics Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000895 acaricidal Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 230000001004 anti-acetylcholinic Effects 0.000 description 1
- 230000002804 anti-anaphylactic Effects 0.000 description 1
- 230000000629 anti-dermatophyte Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003064 anti-oxidating Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000002917 arthritic Effects 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 238000000559 atomic spectroscopy Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229930006719 beta-myrcene Natural products 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000002393 blood protein disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- XCNGEWCFFFJZJT-UHFFFAOYSA-N calcium;azanidylidenecalcium Chemical compound [Ca+2].[Ca]=[N-].[Ca]=[N-] XCNGEWCFFFJZJT-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 201000000297 erysipelas Diseases 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavones Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000021285 flavonoid Nutrition 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229930003935 flavonoids Natural products 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008616 guibi-tang Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002138 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- 230000002439 hemostatic Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 230000002443 hepatoprotective Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000010232 madder color Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1S,4aS,7S,7aS)-7-hydroxy-7-(hydroxymethyl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1H-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000000242 pagocytic Effects 0.000 description 1
- 230000001314 paroxysmal Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940114148 picric acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930002876 rutin Natural products 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000004642 transportation engineering Methods 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003639 vasoconstrictive Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 230000002087 whitening Effects 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
Abstract
本发明公开了一种治疗过敏性紫癜病的药,属中医药技术领域,其特点是它包括黄芪10-30份,党参10-30份,白术3-30份,灵芝3-15份,当归3-30份,水牛角5-60份,三七3-5份,金银花10-60份,连翘6-16份,白芍9-18份,生地9-30份,茜草10-15份,白鲜皮4-15份,甘草2-10份,鹿角胶5-20份,本发明组方合理,可收到兼治各种类型过敏性紫癜,同时有服用方便,无毒副作用,并具有治病疗程短,疗效高且不复发等优点,服用2-4个月,95%以上的过敏性紫癜均能收到良好的临床效果。
Description
本发明涉及的一种治疗过敏性紫癜病的药,属中医药技术领域。
过敏性紫癜是一种较常见的内科病,其临床症状为双下肢皮下斑状及小点状出血,点状呈紫红色且按压后不褪色。中医理论认为,本病的主要病因是脾虚不能摄血,热毒伤络,致血妄行,血瘀于肌表。部分患者还因禀赋不耐而素质虚弱,饮食不调伤及脾气,气不摄血,血不归经,溢于外表而酿成紫斑,临床表现为气虚不摄证(胃肠型),可导致腹痛、便血等;有的患者肾阴亏损,虚火伤及血络,除皮肤有紫斑外尚有肾虚症状,临床表现为肾虚火旺证(肾虚型),伴有肾脏出血,医学上叫紫癜肾,还可出现浮肿和高血压等,肾炎是本病的主要并发症;有的患者因风湿内侵,伤及血络,阴滞经脉,因而出现紫斑,有伴关节肿痛,活动障碍等,临床表现为风湿蕴阻证(关节型)。现代医学研究认为,病毒感染、化学类物质致敏及机体免疫能力低下等也可导致本病的发生。本病近年来有逐年上升的趋势,发病人群以未成年人为主,患者除紫癜等表现外还常伴有肾虚型、胃肠型或关节型,或两型兼有。本病的临床治疗西药尚无一种特效药,西医以激素和抗过敏治疗为主,该方法副作用大,易复发,患者经济负担大。中医传统的治疗方法均为对症治疗:对一般的过敏性紫癜,采用清热凉血化斑的治疗方法,通常用犀角地黄汤等;对胃肠型采用补气摄血化斑法,通常用归脾汤等;对肾虚型,采用滋阴降火退斑法;对关节型则采用祛风祛湿、化斑止痛法,常用独活寄生汤等。以上方法均疗程长,服用不便,患者经济负担重且不能兼顾治疗不同类型的病症。到目前为止,无论西医、中医尚未发现一种能对本病各类病症兼治的有效药物或中成药。
本发明的目的旨在改进上述已有药物的不足,提供一种疗效显著,能对各类并发症兼治且愈后不复发,疗程短,毒副作用小,患者经济负担轻,服用方便的治疗过敏性紫癜的中药。
为了达到上述目的,本发明的组方原则是:健脾益气,养血归经,清热解毒,凉血止血。
本发明所述的一种治疗过敏性紫癜的药,它包括黄芪10-30份,党参10-30份,白术3-30份,灵芝3-15份,当归3-30份,水牛角5-60份,三七3-5份,金银花10-60份,连翘6-16份,白芍9-18份,生地9-30份,茜草10-15份,白鲜皮4-15份,甘草2-10份,鹿角胶5-20份。
黄芪味甘性微温,归脾、肺二经。具有补气升阳、益卫固表、托毒生肌、利水消肿之功效。能益脾补肺、振奋元阳、健中州、升清阳、补肺气、行血脉,布精微、养脏腑、统血液,为补气升阳之良品;且有扶正气、壮元阳、托疮毒、开皮腠、祛邪毒、强肌肉的作用,为托毒、排脓、生肌之要药。主要用于脾肺气虚、脾弱水肿、气虚血滞、表虚不固及正气虚弱之疮痛肿毒、风湿、水肿等证。黄芪含糖类、胆碱、叶酸及多种氨基酸、β-谷甾醇等。具有兴奋神经系统,能增强网状内皮系统的吞噬能力,能使冠状血管和肾脏血管扩张,并对全身末梢血管亦有扩张作用,能加强毛细血管抵抗力。黄芪与党参配伍对肾炎蛋白尿有较好治疗作用。
党参性甘味平,归脾肺二经,有补中益气、养血生津之功效。本品味甘气平,不腻不燥,补中州、和脾胃、升清阳、益肺气,为补脾胃气虚之常品,同时其性主升,能益脾胃、助运化、布水道、生阴血,故为生津润燥养血之药。常用于脾胃虚弱、血虚津伤、中气不足及慢性出血疾患引起的气血两虚之病症。现代研究表明,党参含有皂甙、蛋白质、维生素B1、B2、蔗糖、菊糖、生物碱等,对神经系统有兴奋作用;能增强网状内皮系统的吞噬作用,提高机体抗病能力;能扩张周围血管及抑制肾上腺素而呈降压作用;对放、化疗引起的白血球下降有使其升高作用。
白术味甘性温,归脾、胃二经。有补脾益气、燥湿利水、固表止汗的功效。本品甘缓苦燥,质润气香,能缓胃消谷,健脾胃、运精微、升清阳、补气血、养心神、长肌肉,为健脾补气之要药,同时能温运脾胃,化湿醒脾,益气利窍,健脾除湿,消痰逐水,还能温分肉、实腠理、补营气、生卫气、谐营卫。主要用于脾胃气虚、中气下陷、运化失常导致之饮食减少、脘腹虚胀、倦怠乏力等证。白术含苍术醇、苍术酮等挥发油,并含维生素A、维生素D等。有促进肠胃分泌的作用;有明显的利尿作用,且能促进电解质特别是钠的排出;有降低血糖、保护肝脏、防止肝糖元减少的作用;水煎剂给小鼠灌服(6g/kg)一个月后,能促进小鼠的体重增加和机体增强。
灵芝味甘微苦性微温,归心脾、肺、肝、肾经。具有补气益血、养心安神、止咳平喘之功效。主要用于心脾虚损,气血不足所致的失眠多梦、心悸健忘、体倦神疲,还可治肝炎、克山病、白细胞减少等。灵芝子实体及菌丝含糖类(多糖、还原糖)、氨基酸、蛋白质、甾类、三萜类、油脂类、生物碱、甙、香豆精甙、挥发油、维生素等多种物质。据药理研究,本品能增强中枢神经系统功能,并有调节血压、护肝、促进周围血液中白细胞增加、增强机体免疫能力,并有抗过敏作用,赤芝多糖部分有明显的强心作用,酸类部分有明显的抗过敏作用。
当归味甘辛微苦性温,归肝、心、脾经。有补血活血、调经止痛、润肠通便之功效。本品气轻味浓,能走能守,如心肝能生阴化阳、养血活血,走脾经、能行滞气而散精微、化生补血,且辛散通行,可补可破,能养血调肝、散瘀行滞、和血缓急、调经止痛。临床主要用于补血活血、止痛散瘀、跌打损伤、风湿痹痛、疮痈肿痛等。当归含挥发油、亚叶酸、烟酸、蔗糖、β-谷甾醇、维生素B12等。维生素B12及叶酸类物质具有抗恶性贫血作用;当归能保护肝脏,防止肝糖元减少;另外还有抗维生素E缺乏症,同时有镇静、镇痛及消炎作用;当归注射液做敏感点、神经于、静脉注射,可治疗血栓性脉管炎,能缓解疼痛、促进局部血液循环、提高皮肤温度、阻止肢体坏死的发生和发展,已坏死部分能促进愈合好转。
三七味甘微苦性温,归肝、肾经。具有止血化瘀、消肿止痛之功效。三七走血分,善和营止血、化瘀生新、行滞通脉、能止血妄、化瘀血、和脉络、通血滞、生新血,为上中下血症之要药,有止血不留瘀的特点;且能苦泄行滞、化瘀止痛、温痛活络、散瘀消肿。临床主要用于各种出血症及瘀血阻滞所致的疼痛等证。三七含多种皂甙主要为甲、乙两种皂甙,黄酮甙及生物碱。三七水浸剂对新城疫病毒和多种皮肤真菌具有不同程度的抑制作用,能缩短家兔的凝血时间,对大鼠因注射蛋白、甲醛、右旋糖酐所引起的关节炎有明显的预防治疗作用;三七皂甙甲、乙对蛙心有强心作用,对血管有收缩作用,高浓度呈扩张作用;三七黄酮有明显的增加冠脉血流量、降低动脉压、略减心率以及减少心肌含氧量等作用;三七能明显地促进小鼠肝糖元的增加,三七配伍白茅根、生地等,可治血小板减少性紫癜。
水牛角味苦咸性寒,归心肝胃经,具有凉血止痛,泻火清毒之效,主要用于温热病高热、斑疹、身热发疹,其色紫暗等症,本品代犀角治疗温热症及小儿热症,疗效良好,已被天津、广东、江西等地试验证明。本品药理作用与犀角相似。
金银花味甘性寒,归肺、胃、大肠经。具有清热解毒、凉血止痢的功效。本品清热解毒力颇强,长于清气分热邪、透营达气、解火毒、消痛肿,为疮疡要药;且性寒而气香,善解热毒、消壅滞、凉血热、止泻痢。主要用于温热病及疮、痈、疖肿、热毒壅盛之症。金银花含挥发油(方樟醇占19.95%)、绿原酸、异绿原酸、肌醇、β-谷甾醇、肉豆蔻酸、棕榈酸、双花醇、蔗糖等。双花醇有较强的体外抑菌作用,方樟醇具有抗菌抗病毒作用。
连翘味苦性微寒,归心、肝、胆、小肠经。有清热解毒、消肿散结的功效。本品轻扬、味苦性寒,具升浮宣散、透营达表之力,与金银花功效相似,但连翘则侧重清里而消壅滞,金银花长于解表热而凉血消痛,二者相须为用,效力尤佳。常用于外感风热、温热病初起、疮痈肿毒,可用于乳痛、乳核、瘰疠。连翘含甾醇、酚性成份、生物碱、皂甙、香豆精类,还有丰富的维生素P及少量挥发油。连翘具有较广的抗菌作用,所含维生素P可降低血管通透性,防止渗血;水煎剂有镇吐作用。
白芍味苦酸性微寒,归肝、脾二经。具养血敛阴、柔肝止痛、平抑肝阳之效。白芍苦酸而阴柔,入肝经血分,能化阴补血、和经敛阴,补肝血而养经脉、敛阴精以和营卫,为肝家要药;且味性酸寒,能补能泄,补肝血、敛肝阳、疏脾土,调肝血以缓孪急,柔肝止痛而疗泄泻。常用于肝血不足,月经不调、痛经、腹痛、腹泻、胸胁疼痛及营卫不和之自汗、盗汗。本品含挥发油、苯甲酸、鞣质、芍药甙、牡丹酚、β-谷甾酸、芍药碱、树脂、脂肪油等。水煎剂对痢疾杆菌、溶血型链球菌、肺炎双球菌、大肠杆菌、绿脓杆菌、金黄色葡萄球菌、伤寒杆菌等有抗菌和抑制作用;1∶3水浸剂对多种皮肤真菌有抑制作用;有抑制中枢性疼痛和脊髓性反射弧兴奋的作用;甘草有镇静、抑制末梢神经的作用,二者同用,可治疗中枢性或末梢性的肌肉痉挛以及因痉挛而引起的疼痛等症;临床证明,白芍治疗痢疾及肠胃蠕动而引起的腹痛有疗效。
生地味甘苦性寒,归心、肝、肾经。具有清热滋阴、凉血止血、养阴生津之功。生地质润苦寒,其性平和,能清心热、滋阴液、泻腑热、滑大肠,通小便,且能泄阳明平火,凉血热而归经。主要用于血热妄行之温热病,热入血分之斑,疹症及消渴症;也可用于小便不通,月经过多等。生地含地黄素、甘露醇、葡萄糖、铁质、维生素A等。生地对皮肤真菌有抑制作用;其提取物可促进血液凝固而有止血作用;有强心作用,中等剂量对蛙心有显著的强心作用,对衰弱的心脏更为明显,大剂量能使正常的蛙心中毒;有利尿作用,利尿的原因是于强心作用或与扩张肾脏血管有关。
茜草味苦性寒,归肝经。有凉血止血、活血祛瘀之效。茜草味苦气寒,善走血分,能清血中之热,消壅积之瘀,泻肝火以制阳,凉血热而和阴,为清热凉血之要药;且能行血气、疏经络、消瘀滞、通关节、利腰膝。茜草功专凉血止血、行血通经,为止血而不留瘀之品。临床常用于血热妄行导致的各种出血症,另为妇科调经之良药。茜草含茜草素、茜素、伪紫茜素、茜草色素、茜根酸等。茜草浸出液有止血作用,给家兔适量浸液有明显促进血液凝固作用,体外实验发现茜草对凝血有促进作用;茜草炒炭后对缩短小鼠出血时间比原生药显著;对金黄色葡萄球菌、大肠杆菌有抑制作用;水煎剂有抑制作用;水煎剂能对抗乙酰胆碱的收缩作用,水提取物对豚鼠子宫有收缩作用,临床亦有加强子宫收缩作用;有抗氧化及调节能量代谢作用,给小鼠的茜草提出物,可使心肌及脑中ATP含量明显增加,有利于能量代谢及氧效应的调节。
白鲜皮味苦性寒,归脾、胃经,有清热解毒,祛风止痒之功效。白鲜皮气味甚烈,能彻上彻下,走表达里,燥湿清热,祛风止痒,为湿热疮汤常用之品。临床常用于湿热疮毒、风疹、湿疹、疥癣等。白鲜皮浸出液对刺激发热的家兔有解热作用,对红色表皮癣菌等多种皮肤真菌有抑制作用。
甘草味甘性平,归十二经,具有益气补中、清热解毒、祛痰止咳、缓急止痛、调和药性之效。甘草味厚气浓,其性平和,能益气补虚、缓中健脾、通行百脉、滋养五脏、强壮肌肉、安神养心;且能散邪泻火、消除积热、解毒清痈;本品甘缓善行,善走诸经,能润燥养筋缓急;能缓中补虚、调和药味、缓解峻猛、固护正气。临床常用于脾胃气虚、心血不足、胃肠气滞、热毒炽盛之疮疡肿毒、腹中挛急疼痛,还可用于调和药味、缓和烈性以及解食物、药物中毒等。甘草含有甘草甜素、甘草酸、甘草次酸、葡萄糖醛酸、钙盐等,甘草甜素及其钙盐的解毒作用很强,特别对白喉毒素有强大解毒作用,对于过敏性疾患、河豚毒、蚊毒皆有效果,其解毒机制是多方面的,包括葡萄糖醛酸的结合解毒作用,甘草次酸类的肾上腺皮脂素样作用,甘草甜素吸附作用等;甘草浸膏有抑制组织胺所引起的胃酸分泌作用;有抗胃酸及缓解胃肠平滑肌的作用,粉剂用于溃疡病,能在溃疡面形成薄膜而有保护作用;有似皮质激素作用;对结核杆菌有抑制作用;甘草煎剂外洗可治过敏性皮炎;甘草与金银花、连翘配伍可用于治疗热毒瘀结而致疮痈肿毒、红肿疼痛者。
鹿角胶味甘成性温,有补益肝肾、益精补血之效。主治肾气不足,虚劳羸瘦,腰痛,男子阳痿滑精,妇女子宫虚冷,带下,阴疽。含胶质、磷酸钙、氮化物及各种氨基酸等。各种氨基酸含量为(%):天门冬氨酸5.352,苏氨酸1.969,丝氨酸2.586,谷氨酸9.606,脯氨酸11.548,甘氨酸19.182,丙氨酸2.462,半胱氨酸0.368,缬氨酸2.462,蛋氨酸0.170,亮氨酸2.932,异亮氨酸1.247,酪氨酸0.738,苯丙氨酸2.246,赖氨酸3.355,氨0.815,组氨酸0.705,精氨酸6.930,总量80.178。微量元素为(ppm):Cu11,Zn9,Pb113,Ni3(原子光谱法),Al78.9,Fe0.8,Mn2.2,Ba0.8,Ti1.0(等离子体光谱法)。
为进一步提高健脾益气、清热解毒、凉血止血的功效,本发明还包括:栀子3-10份,紫草3-10份,白茅根15-30份,槐花8-16份,小蓟15-30份。
栀子味苦性寒,归心、肝、肺、胆、胃、三焦经。有泻火除烦、清热利湿、凉血止血、消肿之功效。本品体性轻浮、气厚味降,能泻肺火、清心热、解郁热、行结气,且气清而寒,能解肌表、泻湿热、调气滞、利小便;还主降泄,能泻火凉血、行血消肿。临床主要用于清泄三焦之火邪而除烦,亦可用于血热妄行、吐血衄血、外伤、火疮、丹毒等。栀子含黄酮类、熊果酸、鞣质、藏红花酸、栀子甙、栀子次甙等,其水浸剂有抑制真菌作用;对吐血、衄血、血痢、下血、血淋、损伤血瘀等多种血症有较好疗效。
紫草味甘性寒,归心、肝经。有凉血透疹、解毒疗疮之功。紫草性寒、色紫入血,善清血分之热,能行血滞、凉血热、泻热毒、解痘毒,其性平和,凉血不竣,活而不妄,为解毒透疹之要药;且能清火邪、解热毒,去恶腐、敛水湿、消疮肿、杀疥虫、导大便、利水道。主要用于痘疹、斑疹紫暗之症,也可用于痈疮、疮疥、烫火伤、玫瑰斑疹等。紫草含紫草素(水解后形成紫草醌,是萘醌的衍生物,结构类似维生素K)、色素(紫草红)等。其浸液有抗皮肤真菌的作用;有缓和解热作用;有抗垂体促性腺激素及绒毛膜促性腺激素的作用,对绒毛膜上皮癌有一定的控制作用。
白茅根味甘性寒,归肺、胃、膀胱经。有凉血止血、清热利尿之功。本品甘寒多液,走血分、善利上下诸阳以析火,荡涤胃肠伏热而和中,能泄胃火、除伏热、凉血热、散瘀结、生肺津、益脾胃,有清热而不燥、和中而不呆腻、凉血不留瘀的特点,为血热妄行、诸失血之要药;且能上清肺金、降肺气,下泄积热、利小便。临床主要通过泄火凉血、荡涤伏热而奏效。常用于热证、吐血、衄血、尿血,还可用于热淋及消渴水肿之症。白茅根含甘露醇、葡萄糖、果糖、蔗糖、柠檬、苹果酸、薏苡素、三萜成份、钾盐等。对金黄色葡萄球菌、痢疾杆菌有抑制作用;白茅根的水浸剂试验于家兔,证明有利尿作用;白茅花水浸剂有缩短凝血时间及出血时间等,并能降低血管通透性。
槐花味苦性微寒,归肝、大肠经。有凉血止血、清肝泄火、降血压之功。槐花体轻气薄,性主下行,善清上滞下、凉血坚阴,能泄肺逆、降肝火、泻心火、凉大肠、坚肾水、养阴血,为泻火凉血之佳品,以苦寒泻火、凉血养阴为其见长。临床主要用于血热妄行之出血证。槐花含芸香甙(又名芦丁)、槐花甲素、槐花丙素(为甾醇化合物)、鞣质、绿色素、油脂、挥发油及维生素A类物质。槐花煎剂对麻醉狗有暂时而又显著的降压作用。槐花能缩短出血时间,炭炒后作用更甚。芸香甙有降低毛细血管脆性及毛细血管壁通透性作用。
小蓟味甘性凉,归心、肝经。有凉血止血、消散痛肿及利尿之效。小蓟性凉濡润走血分,能升能降、能破能止,尤以清热凉血、滋阴养血、消瘀行滞较为擅长,且能清火疏风以消肿、散火郁壅滞而除痈肿,为凉血止血之常用品。是通过清热凉血、泻火消肿而取效。临床上常用于出血热证、解毒疮肿及湿热黄疸、肾炎等。小蓟含生物碱、皂甙等。小蓟能降低血液中胆固醇,收缩血管,缩短凝血时间;此外还有利胆和降血压作用;小蓟浸剂对肺炎双球菌、溶血性链球菌、白喉杆菌、金黄色葡萄球菌等均有抑制作用。
为进一步提高对肾虚型过敏性紫癜的治疗效果,本发明还包括:熟地9-30份,何首乌9-25份,枸杞子6-15份。
熟地味甘性微温,归心、肝、肾经,具有补血调经、滋阴补肾之效。熟地苦甘而温,质润滋腻,能养五脏、化阴血、调肝气、养心血,为血中之血药、补血调经之佳品;能补肾生精、封填骨髓,为峻补肝肾之要药。临床主要用于血虚诸证及肝肾阴虚、骨蒸潮热、盗汗、目昏消渴等。熟地含梓醇地黄素、维生素A类物质、糖类及氨基酸等。熟地酒浸剂对大鼠甲醛性关节炎有明显的抑制作用并有显著的抗增性、渗出作用;药理研究证明,本品还有强心、利尿及抑制血糖作用。
何首乌味甘苦涩性微温,归肝、肾经。有补血生精、通便解毒作用。何首乌苦甘而涩、温而不燥、化阴生血、固涩精气、善补肝肾、健筋骨、乌须发,为补血益精之良药;且性主降泄,能养血润燥、泄热解毒、善疗疮痈瘰疠。临床常用于肝肾不足而致血虚精枯之症,还可用于津枯便秘、痰热所致之瘰疠、疮痈、肠风下血等到症。何首乌含蒽醌衍生物,以大黄酚及大黄泻素为主,其次为大黄酸、甲醚等,并含卵磷脂等,制首乌能使切除胃上腺饥饿小鼠肝糖元升高;其所含卵磷脂为构成神经组织、血球及其它细胞所必须的原料;能减少家兔肠道胆固醇的吸收,阻止胆固醇在肝内沉积,缓解动脉粥样硬化的形成;对离体蛙心有兴奋作用,特别对疲劳的心脏强心作用显著;因含蒽醌类,故有泻下作用,能骤减神经的时值,使神经兴奋,并能增加肌肉的时值,使肌肉麻痹;此外尚发现何首乌有类似肾上腺皮质激素样作用;对结核杆菌、福氏痢疾杆菌有抑制作用。
枸杞子味甘性平,归肝、肾经。有滋补肝肾、益精明目之效。枸杞子味甘性平,质地滋润,能补肝血、益肾精、扶阳气、壮筋骨,为养血补精之要药;且入肝肾能补血生精、润养五脏、壮神退热、养肝明目。临床上常用于肝肾精血亏、阳痿者,与何首乌配伍益精血;还用于腰脊酸痛、须发早白、眼目昏花、下泪等症。枸杞子含胡萝卜素、维生素B1、B2、C、烟酸、钙、磷、铁以及β-谷甾醇、亚油酸等。本品有降低血糖的作用,有轻度抑制脂肪在肝内沉着和促进肝细胞再生并能降低体内胆固醇的作用。
为提高对关节型过敏性紫癜的治疗效果,本发明还包括秦艽6-12份,独活3-10份。
秦艽性苦辛性微寒,入胃、肝、胆经。具有祛风止痛、退热除蒸之效。秦艽苦而不燥、辛能宣散,为风药中之润剂;且拿祛风胜湿、舒筋通络、流利关节、和血止痛;且能清热邪、凉疳热、除湿热、利小便;本品以治下肢关节热痛为主,兼利二便。临床上主要用于风湿、肢节疼痛、筋脉孪急等证,亦可用于中风、肠风便血等。秦艽生物碱甲有退热、镇静、镇痛和抗炎作用实验于白鼠,证明有治关节炎作用;有一定的抗过敏和抗组织胺作用,还能使毛细血管渗透性有明显降低;水和乙醇浸出液有降压作用;乙醇浸出液还对炭疽杆菌、金黄色葡萄球菌、肺炎杆菌、痢疾杆菌、伤寒杆菌、变形杆菌等有抗菌作用;秦艽对动物甲醛性或蛋白性关节炎的疗效较水杨酸为强。
独活味辛苦性微温,入肝、肾膀胱经。有祛风胜湿止痛、解表散寒的功效。独活辛香走窜,升中有降,能散风邪、除伏风,通经络、利关节、胜湿气、止疼痛、开腠理、透毛窍,善治腰脊下肢诸痹痛。临床主要用于痹症,还可用于风寒头痛、腰痛、中风及痈疮初起等,与秦艽、羌活及其它活血祛瘀药配伍可治疗紫癜性下肢关节内出血性疼痛。独活含挥发油、当归醇、佛手柑内脂等,据药理研究,独活有抗关节炎、镇痛、镇静及催眠作用,并能直接扩张血管、降低血压,有兴奋中枢神经作用。
为提高对胃肠型过敏性紫癜的治疗效果,本发明还包括:乌药3-12份,枳壳12-30份。
乌药味辛性温,归肺、脾、肾、膀胱经。具有行气止痛、温肾散寒之功效。乌药辛开温通,上行脾肺、下达肾与膀胱,通理上下诸气,能顺气降逆,宽中快膈、疏散凝滞、散寒止痛;且温通行气,无处不达,能温肾气、散冷气、助气化、固膀胱。本品长于疏理胸腹邪逆之气,散寒暖肾、通行膀胱冷气,临床常用于脘腹诸痛、气滞寒郁性疼痛等,还可用于上气喘急、遗尿、尿频及中风等症。乌药含生物碱及挥发油,挥发油中主要有乌药烷、乌药烃、乌药醇、乌药酸、乌药醇酮、乌药内脂、龙脑等。用乌药长期喂大鼠可使体重增加较快,龙脑可发汗、兴奋、镇痉、驱虫等。
枳壳味苦辛性温,归胃、脾经,具有行气消积,消痰除痞之功效。枳壳气香味厚、走而不守、善泻胃实以开坚结、、行瘀滞而调气机。能破坚结、消胀满、开痰癖、逐痰水、荡腑道、通便秘。本品最宜于积滞内停、气机阻滞而见痞满、胀痛诸症,临床主要用于脾胃气滞、痰结停滞、胸中及热结便秘等,亦可用于泻痢、产后腹痛等。枳壳含枸橘甙、柚皮甙、枸橘素、挥发油(β-月桂烯、α-蒎烯、辛醛、十二烷醛)等。枳壳煎剂对子宫有显著兴奋作用,能使子宫收缩有力,增加其紧张力,甚至出现强直性收缩;且对胃肠有兴奋作用,能使胃肠蠕动收缩节律而有力,对乙酰胆碱引起的兔肠痉挛有拮抗作用;枳壳还有抗过敏作用,能抑制过敏介质的释放。
本发明所述的治疗过敏性紫癜的药具有组方合理,可收到兼治各种类型过敏性紫癜的效果,同时有服用方便、无毒副作用、价格便宜、减少患者经济负担的特点,并具有疗程短、疗效高且不复发等优点。服用2-4个月,95%以上的过敏性紫癜均能收到良好的临床效果。
为了更好地理解与实施,下面结合实施例进一步说明如下:例1,按黄芪10kg,党参10kg,白术3kg,灵芝3kg,当归3kg,水牛角5kg,三七3kg,金银花10kg,连翘6kg,白芍9kg,生地9kg,茜草10kg,白鲜皮4kg,甘草2kg,鹿角胶5kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例2,按黄芪20kg,党参20kg,白术20kg,灵芝10kg,当归20kg,水牛角30kg,三七4kg,金银花30kg,连翘10kg,白芍14kg,生地20kg,茜草12kg,白鲜皮10kg,甘草6kg,鹿角胶12kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例3,按黄芪30kg,党参30kg,白术30kg,灵芝15kg,当归30kg,水牛角60kg,三七5kg,金银花60kg,连翘16kg,白芍18kg,生地30kg,茜草15kg,白鲜皮15kg,甘草10kg,鹿角胶20kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例4,按黄芪15kg,党参15kg,白术5kg,灵芝5kg,当归5kg,水牛角20kg,三七3.3kg,金银花20kg,连翘8kg,白芍12kg,生地12kg,茜草11kg,白鲜皮6kg,甘草4kg,鹿角胶7kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例5,按黄芪18kg,党参18kg,白术18kg,灵芝8kg,当归18kg,水牛角25kg,三七3.5kg,金银花25kg,连翘9kg,白芍13kg,生地18kg,茜草11.5kg,白鲜皮8kg,甘草5kg,鹿角胶9kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例6,按黄芪25kg,党参25kg,白术25kg,灵芝13kg,当归25kg,水牛角50kg,三七4.5kg,金银花50kg,连翘13kg,白芍16kg,生地25kg,茜草13kg,白鲜皮13kg,甘草8kg,鹿角胶15kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例7,按黄芪10kg,党参10kg,白术3kg,灵芝3kg,当归3kg,水牛角5kg,三七3kg,金银花10kg,连翘6kg,白芍9kg,生地9kg,茜草10kg,白鲜皮4kg,甘草2kg,鹿角胶5kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例8,按黄芪20kg,党参20kg,白术20kg,灵芝10kg,当归20kg,水牛角30kg,三七4kg,金银花30kg,连翘10kg,白芍15kg,生地20kg,茜草12kg,白鲜皮10kg,甘草6kg,鹿角胶1 2kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例9,按黄芪30kg,党参30kg,白术30kg,灵芝15kg,当归30kg,水牛角60kg,三七5kg,金银花60kg,连翘16kg,白芍18kg,生地30kg,茜草15kg,白鲜皮15kg,甘草10kg,鹿角胶20kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例10,按黄芪15kg,党参15kg,白术15kg,灵芝5kg,当归15kg,水牛角20kg,三七3.3kg,金银花20kg,连翘8kg,白芍12kg,生地12kg,茜草11kg,白鲜皮6kg,甘草4kg,鹿角胶7kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例11,按黄芪18kg,党参18kg,白术18kg,灵芝8kg,当归18kg,水牛角25kg,三七3.5kg,金银花25kg,连翘9kg,白芍13kg,生地18kg,茜草11.5kg,白鲜皮8kg,甘草5kg,鹿角胶9kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例12,按黄芪25kg,党参25kg,白术25kg,灵芝13kg,当归25kg,水牛角50kg,三七4.5kg,金银花50kg,连翘13kg,白芍16kg,生地25kg,茜草13kg,白鲜皮13kg,甘草8kg,鹿角胶15kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例13,按黄芪10kg,党参10kg,白术3kg,灵芝3kg,当归3kg,水牛角5kg,三七3kg,金银花10kg,连翘6kg,白芍9kg,生地9kg,茜草10kg,白鲜皮4kg,甘草2kg,鹿角胶5kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg,熟地9kg,何首乌9kg,构杞子6kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例14,按黄芪20kg,党参20kg,白术20kg,灵芝10kg,当归20kg,水牛角30kg,三七4kg,金银花30kg,连翘10kg,白芍15kg,生地20kg,茜草12kg,白鲜皮10kg,甘草6kg,鹿角胶12kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,熟地20kg,何首乌18kg,枸杞子10kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、 药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例15,按黄芪30kg,党参30kg,白术30kg,灵芝15kg,当归30kg,水牛角60kg,三七5kg,金银花60kg,连翘16kg,白芍18kg,生地30kg,茜草15kg,白鲜皮15kg,甘草10kg,鹿角胶20kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,熟地30kg,何首乌25kg,枸杞子15kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例16,按黄芪15kg,党参15kg,白术15kg,灵芝5kg,当归15kg,水牛角20kg,三七3.3kg,金银花20kg,连翘8kg,白芍12kg,生地12kg,茜草11kg,白鲜皮6kg,甘草4kg,鹿角胶7kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg,熟地15kg,何首乌12kg,枸杞子8kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例17,按黄芪18kg,党参18kg,白术18kg,灵芝8kg,当归18kg,水牛角25kg,三七3.5kg,金银花25kg,连翘9kg,白芍13kg,生地18kg,茜草11.5kg,白鲜皮8kg,甘草5kg,鹿角胶9kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,熟地18kg,何首乌15kg,枸杞子9kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、 药液一起放入夹层锅中煮至药液于涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例18,按黄芪25kg,党参25kg,白术25kg,灵芝13kg,当归25kg,水牛角50kg,三七4.5kg,金银花50kg,连翘13kg,白芍16kg,生地25kg,茜草13kg,白鲜皮13kg,甘草8kg,鹿角胶15kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,熟地25kg,何首乌22kg,枸杞子13kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例19,按黄芪10kg,党参10kg,白术3kg,灵芝3kg,当归3kg,水牛角5kg,三七3kg,金银花10kg,连翘6kg,白芍9kg,生地9kg,茜草10kg,白鲜皮4kg,甘草2kg,鹿角胶5kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg,秦艽6kg,独活3kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例20,按黄芪20kg,党参20kg,白术20kg,灵芝10kg,当归20kg,水牛角30kg,三七4kg,金银花30kg,连翘10kg,白芍15kg,生地20kg,茜草12kg,白鲜皮10kg,甘草6kg,鹿角胶12kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,秦艽8kg,独活7kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例21,按黄芪30kg,党参30kg,白术30kg,灵芝15kg,当归30kg,水牛角60kg,三七5kg,金银花60kg,连翘16kg,白芍18kg,生地30kg,茜草15kg,白鲜皮15kg,甘草10kg,鹿角胶20kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,秦艽12kg,独活10kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例22,按黄芪15kg,党参15kg,白术15kg,灵芝5kg,当归15kg,水牛角20kg,三七3.3kg,金银花20kg,连翘8kg,白芍12kg,生地12kg,茜草11kg,白鲜皮6kg,甘草4kg,鹿角胶7kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg,秦艽7kg,独活4kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例23,按黄芪18kg,党参18kg,白术18kg,灵芝8kg,当归18kg,水牛角25kg,三七3.5kg,金银花25kg,连翘9kg,白芍13kg,生地18kg,茜草11.5kg,白鲜皮8kg,甘草5kg,鹿角胶9kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,秦艽9kg,独活5kg的比例,准确称取上述各种药物,加水500kg浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例24,按黄芪25kg,党参25kg,白术25kg,灵芝13kg,当归25kg,水牛角50kg,三七4.5kg,金银花50kg,连翘13kg,白芍16kg,生地25kg,茜草13kg,白鲜皮13kg,甘草8kg,鹿角胶15kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,秦艽11kg,独活9kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例25,按黄芪10kg,党参10kg,白术3kg,灵芝3kg,当归3kg,水牛角5kg,三七3kg,金银花10kg,连翘6kg,白芍9kg,生地9kg,茜草10kg,白鲜皮4kg,甘草2kg,鹿角胶5kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg小蓟15kg,乌药3kg,枳壳12kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例26,按黄芪20kg,党参20kg,白术20kg,灵芝10kg,当归20kg,水牛角30kg,三七4kg,金银花30kg,连翘10kg,白芍15kg,生地20kg,茜草12kg,白鲜皮10kg,甘草6kg,鹿角胶12kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,乌药7kg,枳壳20kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例27,按黄芪30kg,党参30kg,白术30kg,灵芝15kg,当归30kg,水牛角60kg,三七5kg,金银花60kg,连翘16kg,白芍18kg,生地30kg,茜草15kg,白鲜皮15kg,甘草10kg,鹿角胶20kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,乌药12kg,枳壳30kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
例28,按黄芪15kg,党参15kg,白术15kg,灵芝5kg,当归15kg,水牛角20kg,三七3.3kg,金银花20kg,连翘8kg,白芍1 2kg,生地12kg,茜草11kg,白鲜皮6kg,甘草4kg,鹿角胶7kg,栀子3kg,紫草3kg,白茅根15kg,槐花8kg,小蓟15kg,乌药4kg,枳壳15kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按每包12g的规格,分装成袋即成。
例29,按黄芪1 8kg,党参18kg,白术18kg,灵芝8kg,当归18kg,水牛角25kg,三七3.5kg,金银花25kg,连翘9kg,白芍13kg,生地18kg,茜草11.5kg,白鲜皮8kg,甘草5kg,鹿角胶9kg,栀子5kg,紫草5kg,白茅根20kg,槐花10kg,小蓟20kg,乌药6kg,枳壳25kg的比例,准确称取上述各种药物,加水浸透为准浸泡24小时,放入锅中,煎煮2小时,弃去药渣的2/3,将余下的药渣、药液一起放入夹层锅中煮至药液干涸后,再放入真空干燥机中烘干,将干燥后的药物经粉碎机粉碎后过100目细筛,按0.5g的规格将药粉装入医用胶囊内,每60粒装成一瓶即成。
例30,按黄芪25kg,党参25kg,白术25kg,灵芝13kg,当归25kg,水牛角50kg,三七4.5kg,金银花50kg,连翘13kg,白芍16kg,生地25kg,茜草13kg,白鲜皮13kg,甘草8kg,鹿角胶15kg,栀子10kg,紫草10kg,白茅根30kg,槐花16kg,小蓟30kg,乌药10kg,枳壳22kg的比例,准确称取上述各种药物,混合后经粉碎机粉碎,过100目细筛,按药粉∶炼蜜=4∶1的比例放入搅拌机中搅拌均匀,按丸量9g的规格用制丸机制成药丸即成。
1、临床诊断与治愈标准1.1参考文献:《实用内科学》(人民卫生出版社1998年第10版,上海医科大学<实用内科学>编委会陈灏珠主编),《皮肤病彩色图谱》(科学出版社1988年出版,虞瑞尧编),《皮肤病临床与病理图谱》(山东科学技术出版社1984年版,山东医学院、山东省皮肤病研究所编著)。
1.2临床诊断标准。本病起病前1-3周有上呼吸道感染史,可有倦怠、乏力、低热、纳差等前驱症状。首起症状以皮肤紫癜为常见,多在前驱症状2-3天出现,常对称性分布,以下肢及臀部多见。约50%病例有腹痛,常发生在出诊的1-7天,位于脐周或下腹部,呈阵发性剧痛。可有压痛但无腹肌紧张。严重者可合并呕吐及消化道出血(呕血、便血)。关节型多见于膝、踝等大关节,呈游走性,可有轻微疼痛或明显的红、肿及活动障碍、反复发作。肾脏病变见于1/2-1/3患者,一般于紫癜出现后1-8周内发生,可持续数月及数年,主要表现为血尿、蛋白尿、水肿、高血压,约60%患者发展为慢性肾炎或肾病综合症。本病的实验室检查:半数患者毛细血管脆性实验阳性,白细胞数轻度至中度增加,伴嗜酸性粒细胞增加,血小板通常均正常,各种止血、凝血试验均正常,50%病例血清IgA增高。肾损害时,尿常规可见红细胞、蛋白、管型,肾功能不全时尿素氮及肌酐增高。
鉴别诊断:本病的皮肤紫癜具有特征性,如果同时伴有胃肠道、关节和肾炎等症状,诊断较易,对少数腹痛症状先于皮肤紫癜的病例应与急腹症相鉴别,有便血者需与出血性肠炎相鉴别,有蛋白尿及肾功能变化时须与其他肾小球肾炎及肾病综合症相鉴别。单纯性紫癜是一种良性紫癜,主要发生于生育年龄的妇女、月经期加重,对全身健康无影响,一般不需治疗;血小板减少性紫癜特征是血小板减少或生成障碍;过敏性紫癜主要见于儿童及青年,6岁以上占多数,春秋季好发。
1.3治愈标准:以紫癜消失、皮损正常,胃肠、关节及肾脏并发症状消失,停药2疗程不复发为治愈。
2、临床资料:自1997年至2000年10月共计治疗过敏性紫癜105例
3、用药方法:每日早晚分两次服用,日用量6g,15天为一疗程,至紫癜消失、皮肤损伤恢复正常即停药。
4、经对上述技术方案的讨论,可以看出,本技术方案中组方所采用的各种药物相互配伍,与健脾益气、养血归经、清热解毒、良性止血的组方原则相符合。
5、典型病例:例1,刘××,女,23岁,栖霞市工商局干部,1997年1月经烟台市毓璜顶医院诊断为过敏性紫癜,并发关节型症状,住院治疗一个半月,因无明显好转来我处治疗,经3个疗程痊愈,随访,至今未复发。
例2,闫××,女,10岁,住栖霞市农业局宿舍,1997年1月经栖霞市人民医院儿科诊断为过敏性紫癜,并发胃肠型症状,住院治疗10天,未见好转,经友人介绍来我处诊治,服药3疗程后痊愈,随访至今未复发。
例3,刘××,女,13岁,住栖霞市寺口供销社一职工的女儿,1997年2月经栖霞市人民医院诊断为过敏性紫癜,并发关节型症状,住院治疗半个月无好转,来我处诊治,服药3个月痊愈,至今未复发。
例4,周×,男,7岁,栖霞市西城镇周家庄人,1997年3月15日经栖霞市人民医院确诊为过敏性紫癜,并发关节型症状,住院治疗10天,未见好转,经别人介绍来我处诊治,服药3个疗程后痊愈,停药至今未复发。
例5,衣××,男,7岁,住栖霞市北批发市场,患者于1997年3月17日经栖霞市人民医院儿科诊断为过敏性紫癜,并发胃肠型症状,经过医院治疗10多天后仍无明显好转,经别人介绍前来我处诊治1个月痊愈,停药后至今仍未复发。
例6,林×,女,18岁,系栖霞市联通公司职工,患者于1999年10月经栖霞市中医院诊断为过敏性紫癜,并发关节型症状,住院1个月后仍无明显好转,经别人介绍来我处诊治,2个月后停药至今仍未复发。
例7,王××,女,8岁,住栖霞市寺口镇,患者于1997年2月经栖霞市人民医院诊断为过敏性紫癜,并发胃肠型症状,在人民医院住院7天后转我处,经服中药1个半月痊愈,至今仍未复发。
例8,邢××,女,40岁,系栖霞市皮鞋厂工人,患者1997年经青岛医学院附院诊断为过敏性紫癜,并发肾型症状,住院治疗很长时间不愈,故经友人介绍于1999年5月来我处诊治,服中药2个月痊愈,至今仍未复发。
例9,苗××,女,37岁,系栖霞市苏家店镇苗家庄村人,患者于1997年2月经市人民医院诊断为过敏性紫癜,因其舅在西安医院工作(主任医师),建议她不用住院在我处服中药治疗,1个半月后痊愈,至今仍未复发。
例10,王××,男,7岁,系栖霞市松山乡东芦头村人,患者于2000年2月经栖霞市人民医院儿科诊断为过敏性紫癜,并发关节型症状,住院10余天无明显好转,经朋友介绍来我处求诊,经服药1个半月后痊愈,停药后至今仍未复发。
Claims (7)
1.一种治疗过敏性紫癜病的药,其特征是它包括黄芪10-30份,党参10-30份,白术3-30份,灵芝3-15份,当归3-30份,水牛角5-60份,三七3-5份,金银花10-60份,连翘6-16份,白芍9-18份,生地9-30份,茜草10-15份,白鲜皮4-15份,甘草2-10份,鹿角胶5-20份。
2.按权利要求1所述的一种治疗过敏性紫癜病的药,其特征是它包括黄芪15-25份,党参15-25份,白术5-25份,灵芝5-13份,当归5-25份,水牛角20-50份,三七3.3-4.5份,金银花20-50份,连翘8-13份,白芍12-16份,生地12-25份,茜草11-13份,白鲜皮6-13份,甘草4-8份,鹿角胶7-15份。
3.按权利要求1所述的一种治疗过敏性紫癜病的药,其特征是它包括黄芪20份,党参20份,白术20份,灵芝10份,当归20份,水牛角30份,三七4份,金银花30份,连翘10份,白芍14份,生地20份,茜草12份,白鲜皮10份,甘草6份,鹿角胶12份。
4.按权利要求1或2或3所述的一种治疗过敏性紫癜病的药,其特征是它还包括栀子3-10份,紫草3-10份,白茅根15-30份,槐花8-16份,小蓟15-30份。
5.按权利要求4所述的一种治疗过敏性紫癜病的药,其特征是它还包括熟地9-30份,何首乌9-25份,枸杞子6-15份。
6.按权利要求4所述的一种治疗过敏性紫癜病的药,其特征是它还包括秦艽6-12份,独活3-10份。
7.按权利要求4所述的一种治疗过敏性紫癜病的药,其特征是它还包括乌药3-12份,枳壳12-30份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN00123995A CN1109554C (zh) | 2000-11-01 | 2000-11-01 | 一种治疗过敏性紫癜病的药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN00123995A CN1109554C (zh) | 2000-11-01 | 2000-11-01 | 一种治疗过敏性紫癜病的药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1319403A CN1319403A (zh) | 2001-10-31 |
CN1109554C true CN1109554C (zh) | 2003-05-28 |
Family
ID=4590280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00123995A Expired - Fee Related CN1109554C (zh) | 2000-11-01 | 2000-11-01 | 一种治疗过敏性紫癜病的药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1109554C (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199586B (zh) * | 2006-12-14 | 2011-12-07 | 北京因科瑞斯生物制品研究所 | 一种用于紫癜的药物 |
CN101396531B (zh) * | 2008-10-09 | 2011-01-26 | 刘运波 | 一种治疗过敏性紫癜的中药 |
CN102114163B (zh) * | 2011-02-19 | 2013-02-20 | 岳淑玲 | 一种治疗过敏性紫癜性肾炎的中药 |
CN102614305A (zh) * | 2012-05-01 | 2012-08-01 | 马守云 | 一种治疗过敏性紫癜的药物 |
CN102755553B (zh) * | 2012-07-17 | 2013-10-30 | 王珉鑫 | 用于过敏性紫癜的紫银赤柏汤 |
CN102949554A (zh) * | 2012-11-06 | 2013-03-06 | 合肥海大生物医药科技有限公司 | 一种治疗过敏性紫癜的中药组合物及其制备方法 |
CN103272115B (zh) * | 2013-06-17 | 2014-07-09 | 张祺 | 一种治疗紫癜的药剂 |
CN103385975B (zh) * | 2013-07-01 | 2015-04-15 | 冯子政 | 治疗血小板低下的中药药物 |
CN103989974A (zh) * | 2014-03-21 | 2014-08-20 | 张春玲 | 一种治疗特禀体质足浴中药及其制备方法 |
CN104000991A (zh) * | 2014-05-16 | 2014-08-27 | 陈洪佳 | 一种治疗原发性血小板减少性紫癜的混合中药 |
CN104248730A (zh) * | 2014-09-29 | 2014-12-31 | 孙号 | 一种治疗血小板减少症的药物组合物及其制备方法 |
CN106853187A (zh) * | 2017-03-06 | 2017-06-16 | 董新芳 | 一种治疗血小板减少性紫癜的药物及其制备方法 |
-
2000
- 2000-11-01 CN CN00123995A patent/CN1109554C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1319403A (zh) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN101810685B (zh) | 一种治疗膝关节炎症的中药组合物及其制备方法 | |
CN102342992B (zh) | 一种用于治疗失眠的中药组合物及其制剂的制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN1109554C (zh) | 一种治疗过敏性紫癜病的药 | |
CN106267120A (zh) | 一种治疗鼻炎的中药制剂及其制备方法 | |
CN103099833A (zh) | 有助于缓解运动疲劳和延缓衰老的软胶囊及其制备方法 | |
CN104524335A (zh) | 一种用于女性内分泌失调调理的药丸及制备方法 | |
CN101095923B (zh) | 一种治疗宫外孕的中药 | |
CN101579471B (zh) | 治疗中医消渴证的药物 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN104906430A (zh) | 一种治疗干眼症的中药制剂及其制备方法 | |
CN104815232A (zh) | 一种治疗原发性肺动脉高压的中药制剂及其制备方法 | |
CN104548049A (zh) | 一种治疗老年性骨质疏松症的中药组合物及其制备方法 | |
CN103330837A (zh) | 一种治疗绝经妇女骨质疏松症的中药组合物 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN102091254B (zh) | 一种用于面部整容后消肿的中药组合物及其制备方法 | |
CN101239128B (zh) | 调经养颜中药组合物及其制备方法 | |
CN104189615B (zh) | 一种治疗崩漏的中药制剂及其制备方法 | |
CN102727738A (zh) | 用于治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN103520686B (zh) | 一种治疗艾滋病腹泻的药物 | |
CN102085274A (zh) | 中药治疗急慢性亚级型白血病的组合及其制备方法 | |
CN102091181A (zh) | 中药治疗急慢性粒细胞型白血病1组合及其制备方法 | |
CN104474440A (zh) | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 | |
CN104042993A (zh) | 缓解产后便秘的中药膏剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |